Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine Pedro Morales-RamírezTeresita Vallarino-KellyVirginia Cruz-Vallejo Original Article 21 March 2017 Pages: 843 - 853
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival Hiroki ItoKeiichi KondoNoboru Nakaigawa Original Article 22 March 2017 Pages: 855 - 861
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer Andrea RoccaLorenzo CecconettoDino Amadori Original Article Open access 24 March 2017 Pages: 863 - 871
Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer JoungSoon JangHoon-Kyo KimJong Wook Shin Original Article 24 March 2017 Pages: 873 - 880
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects Vladimir HanesVincent ChowRichard Markus Original Article Open access 24 March 2017 Pages: 881 - 888
Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study David E. AxelrodSudeepti VedulaJames Obaniyi Original Article 25 March 2017 Pages: 889 - 898
Comparative plasma and tissue distribution of Sun Pharma’s generic doxorubicin HCl liposome injection versus Caelyx® (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague–Dawley rats Vinod BuradeSubhas BhowmickThennati Rajamannar Original Article Open access 27 March 2017 Pages: 899 - 913
Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR Wijith P. MunasingheRajendar K. MittapalliHao Xiong Original Article 27 March 2017 Pages: 915 - 922
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer Heather A. WakeleeScott GettingerPrimo N. Lara Jr. Original Article Open access 28 March 2017 Pages: 923 - 932
Increased ceramide production sensitizes breast cancer cell response to chemotherapy Jing CheYu HuangPeng Zhang Original Article 29 March 2017 Pages: 933 - 941
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study Kenji IkemuraKosuke OshimaMasahiro Okuda Original Article 31 March 2017 Pages: 943 - 949
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement Yuichi NagakawaYuichi HosokawaAkihiko Tsuchida Original Article 04 April 2017 Pages: 951 - 957
Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity Qian TanA. M. JoshuaIan F. Tannock Original Article 04 April 2017 Pages: 959 - 969
Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas Aude IngelsCarina DinhofVéronique Mathieu Original Article 07 April 2017 Pages: 971 - 983
Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis Hongwen CaoHongjie YuFang Liang Original Article 08 April 2017 Pages: 985 - 994
The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study Masahiro KondoYuji HottaKazunori Kimura Original Article 08 April 2017 Pages: 995 - 1001
WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206 Yong-qiang RenHui-jun WangYan-bing Liu Original Article 08 April 2017 Pages: 1003 - 1011
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival Yuji OkudaKazuhiro SatoHiroshi Ito Original Article 08 April 2017 Pages: 1013 - 1020
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer Hideki OhtaTakahiro HayashiShigeki Yamada Original Article Open access 08 April 2017 Pages: 1021 - 1029
Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma Qiang WangHandong WangHui Ding Original Article 09 April 2017 Pages: 1031 - 1041
Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury Cécile TeumaSolenne PelletierStéphane Dalle Original Article 10 April 2017 Pages: 1043 - 1049
Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France Clément BonnetPascaline Boudou-RouquetteAudrey Thomas-Schoemann Short Communication 30 March 2017 Pages: 1051 - 1055